Stockscreener 앱 받기
26.22
2.14%
0.55
시간 외 거래:
26.65
0.43
+1.64%
전일 마감가:
$25.67
열려 있는:
$25.67
하루 거래량:
1.57M
Relative Volume:
1.01
시가총액:
$3.28B
수익:
$415.62M
순이익/손실:
$-2.38M
주가수익비율:
-923.24
EPS:
-0.0284
순현금흐름:
$16.92M
1주 성능:
+12.87%
1개월 성능:
+22.98%
6개월 성능:
-7.48%
1년 성능:
+97.74%
1일 변동 폭
$25.66
$26.66
1주일 범위
$22.95
$26.66
52주 변동 폭
$13.06
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.22 | 3.20B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
[144] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) Slips Slightly as Stock Holds Above Key SupportZero Gamma Level - newsline.com
Arcutis (ARQT) director amends filing to correct indirect share count - Stock Titan
Arcutis Biotherapeutics touts ZORYVE growth, FDA catalysts and cash-flow positive status - MSN
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) reports Q1 loss, beats revenue estimates - MSN
GW&K Investment Management LLC Sells 163,461 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status - sharewise.com
Arcutis (ARQT) director receives RSU grant and 16,667-share stock option - Stock Titan
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Arcutis Stockholders Approve Proposals at 2026 Meeting - TipRanks
Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay - Stock Titan
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors - GlobeNewswire Inc.
Geode Capital Management LLC Has $79.97 Million Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Arcutis hires receive 44,000 restricted stock units - Stock Titan
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 sees revenue beat, EPS miss - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com
ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Chart - ChartMill
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - StreetInsider
New Expert Consensus Provides Age-Specific Guidance for - GlobeNewswire
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Hillsdale Investment Management Inc. Invests $5.21 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
ARQT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
(ARQT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37 - Moomoo
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Globe and Mail
Insiders At Arcutis Biotherapeutics Sold US$4.4m In Stock, Alluding To Potential Weakness - Moomoo
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):